Craft
  • Home
  •  / Innate Pharma
Innate Pharma

Innate Pharma

Phase I Trials Products

3

Q2, 2019

Revenue

€13.9 M

FY, 2021

Market Capitalization

€195.1 M

2022-09-21

Innate Pharma Summary

Company summary

Overview
Innate Pharma is a clinical-stage biotechnology company with a focus on discovering and developing therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. The company’s aim is a commercial-stage biopharmaceutical company in the area of immunotherapy and focuses on the research in medical needs in cancer.
Type
Public
Founded
1999
HQ
Marseille, FR | view all locations
Website
http://www.innate-pharma.com/en
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Herve Brailly

    Herve Brailly, Chairman of the Supervisory Board, Co-founder

    • Odile Laurent

      Odile Laurent, Vice President, Human Resources Director

      • Irina Staatz-Granzer

        Irina Staatz-Granzer, Vice-Chairman

        • Mondher Mahjoubi

          Mondher Mahjoubi, Chairman of the Executive Board and Chief Executive Officer

          Operating MetricsView all

          Phase I Trials Products

          3

          Q2, 2019

          Pre-Clinical Phase Products

          7

          Q2, 2019

          Phase II Trials Products

          5

          Q2, 2019

          LocationsView all

          2 locations detected

          • Marseille, Provence-Alpes-Côte d'Azur HQ

            France

            117 Avenue de Luminy

          • Rockville, MD

            United States

            2273 Research Blvd #350

          Innate Pharma Financials

          Summary financials

          Revenue (FY, 2021)
          €13.9M
          Gross profit (FY, 2021)
          €23.5M
          Net income (FY, 2021)
          (€52.8M)
          Cash (FY, 2021)
          €103.8M
          EBIT (FY, 2021)
          (€55.0M)
          Enterprise value
          $135.6M

          Footer menu